Poseida Therapeutics Announces FDA Clearance of Investigational
134
PSTX: Poseida Therapeutics, Inc. 2021-08-30 08:00:00 Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma